Esophageal Cancer Precursor Detected by Electronic Nose Device
|
By LabMedica International staff writers Posted on 10 Mar 2020 |

Image: Electronic Nose Device Can Detect Esophageal Cancer Precursor (Photo courtesy of Radboud University Medical Center).
Barrett's esophagus is a condition in which the lining of the esophagus changes, becoming more like the lining of the small intestine rather than the esophagus. This occurs in the area where the esophagus is joined to the stomach.
The main cause of Barrett's esophagus is thought to be an adaptation to chronic acid exposure from reflux esophagitis. Barrett's esophagus is diagnosed by endoscopy: observing the characteristic appearance of this condition by direct inspection of the lower esophagus; followed by microscopic examination of tissue from the affected area obtained from biopsy.
Gastroenterologists at the Radboud University Medical Center (Nijmegen, the Netherlands) and their colleagues wanted to see how effective and accurate a portable 'electronic nose' device would be for picking up Barrett's esophagus. Some 402 adults scheduled for endoscopy breathed into a highly sensitive electronic nose, designed to detect subtle differences in volatile organic compounds (VOCs) patterns, for five minutes. Of this group, 129 patients had Barrett's esophagus; 141 had acid reflux disease, including 50 who had an inflamed esophagus as a result; and 132 had a normal esophagus or hiatus hernia that accounted for their symptoms.
Analysis of VOCs profiles detected by the electronic nose showed that these differed significantly among patients with Barrett's esophagus, acid reflux, and those with a normal esophagus/hernia. The sensitivity of the device was 91%, its ability to pick up Barrett's esophagus and its specificity was 74%, its ability to detect those without the condition. When the analysis was further restricted to patients who had been taking drugs (proton pump inhibitors) to curb stomach acid production for at least a month or those with a hiatus hernia, both of which are likely to muddy the diagnostic waters, its accuracy was still good.
The authors concluded that the technique analyzing VOCs with an electronic nose may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy. The study was published on February 25, 2020 in the journal GUT.
Related Links:
Radboud University Medical Center
The main cause of Barrett's esophagus is thought to be an adaptation to chronic acid exposure from reflux esophagitis. Barrett's esophagus is diagnosed by endoscopy: observing the characteristic appearance of this condition by direct inspection of the lower esophagus; followed by microscopic examination of tissue from the affected area obtained from biopsy.
Gastroenterologists at the Radboud University Medical Center (Nijmegen, the Netherlands) and their colleagues wanted to see how effective and accurate a portable 'electronic nose' device would be for picking up Barrett's esophagus. Some 402 adults scheduled for endoscopy breathed into a highly sensitive electronic nose, designed to detect subtle differences in volatile organic compounds (VOCs) patterns, for five minutes. Of this group, 129 patients had Barrett's esophagus; 141 had acid reflux disease, including 50 who had an inflamed esophagus as a result; and 132 had a normal esophagus or hiatus hernia that accounted for their symptoms.
Analysis of VOCs profiles detected by the electronic nose showed that these differed significantly among patients with Barrett's esophagus, acid reflux, and those with a normal esophagus/hernia. The sensitivity of the device was 91%, its ability to pick up Barrett's esophagus and its specificity was 74%, its ability to detect those without the condition. When the analysis was further restricted to patients who had been taking drugs (proton pump inhibitors) to curb stomach acid production for at least a month or those with a hiatus hernia, both of which are likely to muddy the diagnostic waters, its accuracy was still good.
The authors concluded that the technique analyzing VOCs with an electronic nose may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy. The study was published on February 25, 2020 in the journal GUT.
Related Links:
Radboud University Medical Center
Latest Technology News
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
Channels
Clinical Chemistry
view channel
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read more
CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
Specialized care settings frequently evaluate patients aged 50 years and older who present with signs and symptoms of cognitive decline to determine whether amyloid pathology linked to Alzheimer’s disease... Read moreMolecular Diagnostics
view channel
Blood-Based “Ageing Clock” Helps Predict Dementia Risk and Earlier Onset
Dementia imposes a growing health burden, affecting an estimated 982,000 people in the UK, with cases projected to reach 1.4 million by 2040. Earlier identification of those most likely to develop disease... Read more
Blood Test Refines Biopsy Decisions in Prostate Cancer
Prostate biopsy decisions remain challenging, with many men undergoing invasive procedures that ultimately yield negative results. In the U.S., more than a million prostate biopsies are performed each... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








